featured
Oral Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients
Blood 2021 Mar 24;[EPub Ahead of Print], T Facon, CP Venner, NJ Bahlis, F Offner, D White, L Karlin, L Benboubker, S Rigaudeau, P Rodon, E Voog, SS Yoon, K Suzuki, H Shibayama, X Zhang, P Twumasi-Ankrah, G Yung, RM Rifkin, P Moreau, S Lonial, SK Kumar, PG Richardson, SV RajkumarFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.